Abstract
34 novel ATR inhibitors were used to build an optimal 3D-QSAR model. Homology modeling and molecular docking were used to study the interaction of ATR kinase protein and inhibitor. The results showed that both the CoMFA model (q2 = 0.550; r2 = 0.978; standard error of estimate [SEE] = 0.129; F = 177.729 and r2pred = 0.530) and the CoMSIA model (q2 = 0.632; r2 = 0.991; standard error of estimate [SEE] = 0.088; F = 277.224 and r2 pred = 0.322) are acceptable. The 3D-model of ATR kinase was further assessed by ERRAT, WHATCHECK and PROCHECK, which showed that the final model is reliable with 78.9% of the residues in the most favored regions. According to molecular docking, Ala562, Ser563, Leu564 and Lys585 were the vital amino acid residues to the ATR kinase. This article can support useful information for designing novel and high bioactive ATR kinase inhibitors.
Keywords: ATR inhibitor, 3D-QSAR, CoMFA, CoMSIA, Homology modeling, Molecular docking.
Letters in Drug Design & Discovery
Title:Molecular Modeling of Sulfonylmorpholinopyrimidines as the Ataxia Telangiectasis Mutated and RAD3-related (ATR) Protein Kinase Inhibitors by Computational Explorations
Volume: 12 Issue: 8
Author(s): Zhengfeng Li, Zhi Wang and Zhiyi Yao
Affiliation:
Keywords: ATR inhibitor, 3D-QSAR, CoMFA, CoMSIA, Homology modeling, Molecular docking.
Abstract: 34 novel ATR inhibitors were used to build an optimal 3D-QSAR model. Homology modeling and molecular docking were used to study the interaction of ATR kinase protein and inhibitor. The results showed that both the CoMFA model (q2 = 0.550; r2 = 0.978; standard error of estimate [SEE] = 0.129; F = 177.729 and r2pred = 0.530) and the CoMSIA model (q2 = 0.632; r2 = 0.991; standard error of estimate [SEE] = 0.088; F = 277.224 and r2 pred = 0.322) are acceptable. The 3D-model of ATR kinase was further assessed by ERRAT, WHATCHECK and PROCHECK, which showed that the final model is reliable with 78.9% of the residues in the most favored regions. According to molecular docking, Ala562, Ser563, Leu564 and Lys585 were the vital amino acid residues to the ATR kinase. This article can support useful information for designing novel and high bioactive ATR kinase inhibitors.
Export Options
About this article
Cite this article as:
Li Zhengfeng, Wang Zhi and Yao Zhiyi, Molecular Modeling of Sulfonylmorpholinopyrimidines as the Ataxia Telangiectasis Mutated and RAD3-related (ATR) Protein Kinase Inhibitors by Computational Explorations, Letters in Drug Design & Discovery 2015; 12 (8) . https://dx.doi.org/10.2174/157018081208150730160854
DOI https://dx.doi.org/10.2174/157018081208150730160854 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Arthropathy in Patients with CREST Variant Scleroderma
Current Rheumatology Reviews Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Targeting Mast Cells and Basophils in Allergy and Beyond: Emerging Concepts (Executive Guest Editor: Petr Heneberg)]
Current Pharmaceutical Design Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Treatment of Recurrent Epistaxis in HHT
Current Pharmaceutical Design Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design Medical Treatment of Chronic Venous Insufficiency
Vascular Disease Prevention (Discontinued) Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension
Current Vascular Pharmacology Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency
Current Vascular Pharmacology Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Treatment of Choroidal Neovascularization in High Myopia
Current Drug Targets